<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001907'>Thromboembolism</z:hpo> is a common complication related to coil embolization of <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To identify factors related to <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> during coil embolization for unruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> and to evaluate the role of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> premedication to prevent <z:hpo ids='HP_0001907'>thromboembolisms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Since March 2006, <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> has been administered to patients with unruptured <z:hpo ids='HP_0002617'>aneurysms</z:hpo> before coil embolization (the <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> group) in our institution </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> group (416 patients with 485 <z:hpo ids='HP_0002617'>aneurysms</z:hpo>) and the historical control group (140 patients with 159 <z:hpo ids='HP_0002617'>aneurysms</z:hpo> who received no antiplatelet premedication) were compared to find the efficacy of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> premedication </plain></SENT>
<SENT sid="4" pm="."><plain>Various factors, including age, sex, body weight, and medical history of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, smoking, previous <z:hpo ids='HP_0001297'>stroke</z:hpo>, and <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, as well as <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> premedication, were analyzed in relationship to the development of a procedure-related <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Procedure-related <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> tended to occur less frequently in the <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> group compared with the control group (7.4% vs 12.6%; P = .05), and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> premedication could modify the risk in female patients from 11.1% to 5.2% (P = .04) </plain></SENT>
<SENT sid="6" pm="."><plain>The use of multiple logistic regression analysis identified <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> premedication (P = .03), smoking (P = .002), and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> (P = .02) as significant factors related to the formation of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> premedication seems to have a beneficial effect in reducing the number of procedure-related <z:hpo ids='HP_0001907'>thromboembolisms</z:hpo> during coil embolization for unruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo>, especially in female patients </plain></SENT>
<SENT sid="8" pm="."><plain>Smoking and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> were independent risk factors related to <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
</text></document>